Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
- PMID: 28455679
- PMCID: PMC5497590
- DOI: 10.1007/s13679-017-0262-y
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Abstract
Purpose of review: One begins to see improvement in glycemic measures and triglycerides with small amounts of weight loss, but with greater levels of weight loss there is even greater improvement. In fact, the relationship between weight loss and glycemia is one that is very close.
Recent findings: This is fortunate for diabetes prevention; it takes only small amounts of weight loss to prevent progression to type 2 diabetes from impaired glucose tolerance, and after the 10 kg of weight loss, one cannot demonstrate much additional improvement in risk reduction. Modest weight loss (5 to 10%) is also associated with improvement in systolic and diastolic blood pressure and HDL cholesterol. With all these risk factors, more weight loss produces more improvement. Further, for patients with higher BMI levels (>40 kg/m2), the ability to lose the same proportion of weight with lifestyle intervention is equal to that of those with lower BMI levels, and there is equal benefit in terms of risk factor improvement with modest weight loss. For some comorbid conditions, more weight loss is needed-10 to 15%-to translate into clinical improvement. This is true with obstructive sleep apnea and non-alcoholic steatotic hepatitis. There is a graded improvement in improvements in measures of quality of life, depression, mobility, sexual dysfunction, and urinary stress incontinence, whereby improvements are demonstrable with modest weight loss (5-10%) and with further weight loss there are further improvements. For polycystic ovarian syndrome and infertility, modest weight loss (beginning at 2-5%) can bring improvements in menstrual irregularities and fertility. Moderate weight loss (5-10%) has been shown to be associated with reduced health care costs. Reduction in mortality may take more than 10% weight loss, although definitive studies have not been done to demonstrate that weight loss per se is associated with mortality reduction. Clinicians in medical weight management should bear in mind that the target should be health improvement rather than a number on the scale. The individual patient's targeted health goal should be assessed for response rather than a prescribed percentage weight loss.
Keywords: Dysglycemia; Dyslipidemia; Hypertension; Infertility; Non-alcoholic fatty liver disease; Obesity; Obesity comorbidity; Obstructive sleep apnea; Polycystic ovarian syndrome; Type 2 diabetes; Weight loss; Weight loss and comorbidity improvement; Weight management.
Conflict of interest statement
Donna H. Ryana and Sarah Ryan Yockey declare they have no conflict of interest.
Figures
Similar articles
-
[Pharmacological therapy of obesity].G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. G Ital Cardiol (Rome). 2008. PMID: 18773755 Italian.
-
Losing excess weight increases chance of eliminating sleep apnea.Mayo Clin Womens Healthsource. 2010 Mar;14(3):3. Mayo Clin Womens Healthsource. 2010. PMID: 20110860 No abstract available.
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24. Endocr Pract. 2016. PMID: 27219496
-
Children's Hospital Association consensus statements for comorbidities of childhood obesity.Child Obes. 2014 Aug;10(4):304-17. doi: 10.1089/chi.2013.0120. Epub 2014 Jul 14. Child Obes. 2014. PMID: 25019404 Free PMC article. Review.
-
Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift.Diab Vasc Dis Res. 2019 Mar;16(2):118-127. doi: 10.1177/1479164119827611. Epub 2019 Feb 15. Diab Vasc Dis Res. 2019. PMID: 30770030 Review.
Cited by
-
Metabolite, Biochemical, and Dietary Intake Alterations Associated with Lifestyle Interventions in Obese and Overweight Malaysian Women.Nutrients. 2024 Oct 16;16(20):3501. doi: 10.3390/nu16203501. Nutrients. 2024. PMID: 39458496 Free PMC article.
-
Efficacy and safety of traditional chinese medicine treatment for overweight and obese individuals: A systematic review and meta-analysis.Front Pharmacol. 2022 Oct 5;13:964495. doi: 10.3389/fphar.2022.964495. eCollection 2022. Front Pharmacol. 2022. PMID: 36278196 Free PMC article.
-
Association Between Mobile Health App Engagement and Weight Loss and Glycemic Control in Adults With Type 2 Diabetes and Prediabetes (D'LITE Study): Prospective Cohort Study.JMIR Diabetes. 2022 Sep 30;7(3):e35039. doi: 10.2196/35039. JMIR Diabetes. 2022. PMID: 36178718 Free PMC article.
-
Effects of Pharmacotherapy for the Treatment of Obesity in an Urban, Safety-Net Population.Cureus. 2023 Oct 29;15(10):e47922. doi: 10.7759/cureus.47922. eCollection 2023 Oct. Cureus. 2023. PMID: 38034269 Free PMC article.
-
Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review.Diabetes Ther. 2024 Feb;15(2):325-341. doi: 10.1007/s13300-023-01503-4. Epub 2023 Nov 22. Diabetes Ther. 2024. PMID: 37989829 Free PMC article. Review.
References
-
- Williamson DA, Bray GA, Ryan DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? Obesity (Silver Spring) 2015 Dec;23(12):2319–20. - PubMed
-
- Jensen MD, Ryan DH, Donato KA, et al. Guidelines 2013 for managing overweight and obesity in adults. Obesity. 2014;22:S1–S410. These guidelines are based on a systematic evidence review around 5 critical questions (benefits of weight loss, risks of excess body weight, best diet for weight loss, weight loss with comprehensive lifestyle intervention and role of bariatric surgery). - PubMed
-
- U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDEER) Guidance for Industry Developing products for Weight Management. Draft Guidance. 2007 Feb; Revision 1. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati... Accessed 1/7/2017.
-
- Messier RP, Gutekunst DJ, Davis C, DeVita P. ARTHRITIS & RHEUMATISM. 2005;52(7):2026–32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials